BCAX

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company developing innovative therapies for solid tumors by harnessing the power of antibody-based precision combination therapies. Headquartered in Waltham, Massachusetts, Bicara is pioneering bifunctional antibodies that deliver targeted cancer therapy by simultaneously blocking tumor growth signals and activating the immune system against cancer cells. This dual-mechanism approach aims to provide superior efficacy compared to single-agent therapies while maintaining manageable safety profiles. The company's lead candidate is ficerafusp alfa (BCA101), a bifunctional antibody designed to simultaneously bind EGFR (epidermal growth factor receptor) on tumor cells and activate CD28 co-stimulation on T cells, essentially delivering tumor growth inhibition plus immune activation in a single molecule. This approach combines aspects of targeted therapy and immunotherapy, potentially addressing limitations of each modality when used alone. Ficerafusp alfa is being developed for multiple solid tumor types including head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), and other EGFR-expressing cancers. Bicara's bifunctional antibody platform represents a next-generation approach to combination cancer therapy, potentially offering improved efficacy, reduced treatment burden, and better patient convenience compared to administering two separate drugs. The company has generated encouraging clinical data showing anti-tumor activity and manageable safety in ongoing trials. Bicara benefits from an experienced management team with track records in drug development and successful biotech companies. The company is advancing its lead program through clinical trials with the goal of regulatory approval and commercialization.